Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Zanubrutinib and Venetoclax As Initial Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)

John N. Allan, Daniel Helbig, Erin Mulvey, Sarah Nazir, Sandra Stewart, Melissa L. Lapinta, Sarah C. Rutherford, Jia Ruan, John P. Leonard, Peter Martin, Richard R. Furman

Blood (2023) 142 (Supplement 1): 3285.

https://doi.org/10.1182/blood-2023-174465

Published: 2023

Journal Articles

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Seda S. Tolu, Caitlin Gribbin, Madhav R Seshadri, Zhengming Chen, Evelyn Orlando, Justin Grenet, Rajbir Toor, Alexander Sanjurjo, Adrienne A. Phillips, Tsiporah B. Shore, Peter Martin, John P. Leonard, Barbara Pro, Jennifer E. Amengual, Jia Ruan

Blood (2023) 142 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2023-178231

Published: 2023

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma

Maurizio Di Liberto, Yang Hu, Xiangao Huang, Giorgio Inghirami, Kevin Wang, Christina Lee, Kami J. Maddocks, Kristie A. Blum, Jia Ruan, John P. Leonard, Nancy L. Bartlett, Peter Martin, Olivier Elemento, Selina Chen-Kiang

Blood (2023) 142 (Supplement 1): 50.

https://doi.org/10.1182/blood-2023-190308

Published: 2023

Journal Articles

Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study

Blood (2023) 142 (Supplement 1): 3079.

https://doi.org/10.1182/blood-2023-180318

Published: 2023

Journal Articles

A National Cancer Database Study of Survival Trends in Patients with Mantle Cell Lymphoma Stratified By Age Group

Jacqueline F. Wang, Jihao Zhou, Steven R Hwang, Catherine S Diefenbach, Jia Ruan, Peter Martin, Jonas Paludo, Javier L. Munoz, Stephen M Ansell, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan, Grzegorz S. Nowakowski, Yucai Wang

Blood (2023) 142 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2023-179611

Published: 2023

Journal Articles

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Blood (2023) 141 (18): 2194–2205.

https://doi.org/10.1182/blood.2022018254

Published: 2023

Includes: Supplemental data

Journal Articles

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study

Blood (2022) 140 (Supplement 1): 3666–3668.

https://doi.org/10.1182/blood-2022-164988

Published: 2022

Journal Articles

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Jia Ruan, John P. Leonard, Gui Zhen Chen, Zhengming Chen, John N. Allan, Sarah C. Rutherford, Brittany Hobbie, Katie Greig, Amelyn Rodriguez, Wayne Tam, David A. Bond, Bijal D. Shah, Kami J. Maddocks, Bhavneet Binder, Giorgio Inghirami, Olivier Elemento, Selina Chen-Kiang, Peter Martin

Blood (2022) 140 (Supplement 1): 175–177.

https://doi.org/10.1182/blood-2022-158656

Published: 2022

Journal Articles

Claiming the mantle of the brain

Jia Ruan

Blood (2022) 140 (17): 1835–1836.

https://doi.org/10.1182/blood.2022017285

Published: 2022

Journal Articles

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Blood (2021) 138 (26): 2828–2837.

https://doi.org/10.1182/blood.2021013379

Published: 2021

Includes: Supplemental data

Journal Articles

Terraflow, a New High Parameter Data Analysis Tool, Reveals Systemic T-Cell Exhaustion and Dysfunctional Cytokine Production in Classical Hodgkin Lymphoma

Dan Freeman, Linda Lam, Tri Li, Jason Alexandre, Bruce G. Raphael, David Kaminetzky, Jia Ruan, Pratip Chattopadhyay, Catherine S. Diefenbach

Blood (2021) 138 (Supplement 1): 3516.

https://doi.org/10.1182/blood-2021-149154

Published: 2021

Journal Articles

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Blood (2021) 138 (Supplement 1): 138.

https://doi.org/10.1182/blood-2021-145495

Published: 2021

Journal Articles

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134699

Published: 2020

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

Samuel Yamshon, MD, Peter Martin, FRCPC, MD MS, Bijal Shah, MD, Stephen J. Schuster, MD, Paul J Christos, Dr.P.H., M.S., Amelyn Rodriguez, BSN, RN, OCN, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Sarah C. Rutherford, MD, John N. Allan, MD, John P. Leonard, MD, Jia Ruan, MD PhD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-138731

Published: 2020

Journal Articles

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, MD PhD, Alison J. Moskowitz, MD, Neha Mehta-Shah, MD, Lubomir Sokol, MD PhD, Zhengming Chen, PhD MPH, MS, Riyaad Rahim, Wei Song, Koen Van Besien, MD PhD, Steven M. Horwitz, MD, Sarah C. Rutherford, MD, Morton Coleman, MD FACP, Ari Melnick, MD, Giorgio Inghirami, MD, Leandro Cerchietti, MD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136023

Published: 2020

Journal Articles

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-138542

Published: 2020

Journal Articles

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Christina Y. Lee, MD, Kevin Wang, B.S., Nancy L. Bartlett, MD, LeAnn Ridling, Kristie A. Blum, MD, Kami J. Maddocks, MD, Steven I Park, MD, Jia Ruan, MD PhD, Kenneth Eng, B.S., Lorenzo Galluzzi, PhD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 1492.

https://doi.org/10.1182/blood-2019-130944

Published: 2019

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Stefan K. Barta, MD MRCP, MS, Nathan H. Fowler, MD, Jasmine Zain, MD, Jia Ruan, MD PhD, Sonali M. Smith, MD, Stephen J. Schuster, MD, Sunita D Nasta, MD, Jakub Svoboda, MD, James N Gerson, MD, Daniel J. Landsburg, MD, Elise A. Chong, MD, Henry C. Fung, FRCP,MBBChir, Kerry S Campbell, PhD, Nadia Khan, MD, Richard I. Fisher, MD, Carlyn Rose Tan, MD

Blood (2019) 134 (Supplement_1): 4031.

https://doi.org/10.1182/blood-2019-125385

Published: 2019

NARROW

Zanubrutinib and Venetoclax As Initial Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma

Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study

A National Cancer Database Study of Survival Trends in Patients with Mantle Cell Lymphoma Stratified By Age Group

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Claiming the mantle of the brain

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Terraflow, a New High Parameter Data Analysis Tool, Reveals Systemic T-Cell Exhaustion and Dysfunctional Cytokine Production in Classical Hodgkin Lymphoma

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only